Association Between Late-Life Neuropsychiatric Symptoms and Cognitive Decline in Relation to White Matter Hyperintensities and Amyloid Burden
- PMID: 35213370
- PMCID: PMC9969328
- DOI: 10.3233/JAD-215267
Association Between Late-Life Neuropsychiatric Symptoms and Cognitive Decline in Relation to White Matter Hyperintensities and Amyloid Burden
Abstract
Background: Neuropsychiatric symptoms (NPS) among cognitively normal older adults are increasingly recognized as risk factors for cognitive decline and impairment. However, the underlying mechanisms remain unclear.
Objective: To examine whether biomarkers of Alzheimer's disease (amyloid burden) and cerebrovascular disease (white matter hyperintensity (WMH) volume) modify the association between NPS and cognitive decline among cognitively unimpaired older adults.
Methods: Analyses included 193 cognitively unimpaired participants (M age = 70 years) from the BIOCARD study, including 148 with PET amyloid and WMH biomarker data. NPS were measured with Neuropsychiatric Inventory and Geriatric Depression Scale scores. Linear mixed effects models were used to examine the association between baseline NPS and longitudinal cognitive trajectories (M follow-up = 3.05 years), using separate models for global, episodic memory, and executive function cognitive composite scores. In a subset of individuals with biomarker data, we evaluated whether WMH or cortical amyloid burden modified the relationship between NPS and cognitive change (as indicated by the NPS×biomarker×time interactions).
Results: Higher baseline NPS were associated with lower executive function scores, but not a faster rate of decline in executive function. NPS symptoms were unrelated to the global or episodic memory composite scores, and there was little evidence of a relationship between NPS symptoms and cognitive change over time. The associations between NPS and cognitive decline did not differ by amyloid or WMH burden, and NPS were unrelated to amyloid and WMH burden.
Conclusion: These results suggest that the effect of neuropsychiatric symptoms on executive dysfunction may occur through mechanisms outside of amyloid and cerebrovascular disease.
Keywords: Alzheimer’s disease; amyloid; depression; mild behavioral impairment; neuropsychiatric symptoms; white matter hyperintensities.
Similar articles
-
White matter hyperintensities and cognition across different Alzheimer's biomarker profiles.J Am Geriatr Soc. 2021 Jul;69(7):1906-1915. doi: 10.1111/jgs.17173. Epub 2021 Apr 23. J Am Geriatr Soc. 2021. PMID: 33891712 Free PMC article.
-
Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer's Coordinating Center Uniform Data Set.Alzheimers Res Ther. 2019 Jul 27;11(1):64. doi: 10.1186/s13195-019-0521-0. Alzheimers Res Ther. 2019. PMID: 31351489 Free PMC article.
-
White matter hyperintensities and neuropsychiatric symptoms in mild cognitive impairment and Alzheimer's disease.Neuroimage Clin. 2020;28:102367. doi: 10.1016/j.nicl.2020.102367. Epub 2020 Jul 31. Neuroimage Clin. 2020. PMID: 32798911 Free PMC article.
-
White matter hyperintensities are higher among early-onset Alzheimer's disease participants than their cognitively normal and early-onset nonAD peers: Longitudinal Early-onset Alzheimer's Disease Study (LEADS).Alzheimers Dement. 2023 Nov;19 Suppl 9(Suppl 9):S89-S97. doi: 10.1002/alz.13402. Epub 2023 Jul 25. Alzheimers Dement. 2023. PMID: 37491599 Free PMC article. Review.
-
Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer's disease and cognitively unimpaired individuals.Transl Neurodegener. 2021 Mar 31;10(1):11. doi: 10.1186/s40035-021-00236-3. Transl Neurodegener. 2021. PMID: 33789730 Free PMC article. Review.
Cited by
-
Unraveling the Potential Underlying Mechanisms of Mild Behavioral Impairment: Focusing on Amyloid and Tau Pathology.Cells. 2024 Jul 8;13(13):1164. doi: 10.3390/cells13131164. Cells. 2024. PMID: 38995015 Free PMC article. Review.
-
Neuropsychiatric symptoms and white matter hyperintensities in older adults without dementia.Int Psychogeriatr. 2024 Nov;36(11):1051-1063. doi: 10.1017/S1041610224000607. Epub 2024 Apr 19. Int Psychogeriatr. 2024. PMID: 38639110 Free PMC article.
-
Neuropsychiatric Profiles and Cerebral Amyloid Burden in Adults without Dementia.Dement Geriatr Cogn Disord. 2024;53(3):119-127. doi: 10.1159/000538376. Epub 2024 Mar 21. Dement Geriatr Cogn Disord. 2024. PMID: 38513620 Free PMC article.
-
Mapping the Neuropsychiatric Symptoms in Alzheimer's Disease Using Biomarkers, Cognitive Abilities, and Personality Traits: A Systematic Review.Diagnostics (Basel). 2025 Apr 24;15(9):1082. doi: 10.3390/diagnostics15091082. Diagnostics (Basel). 2025. PMID: 40361900 Free PMC article. Review.
-
Updates and future perspectives on neuropsychiatric symptoms in Alzheimer's disease.Alzheimers Dement. 2025 Mar;21(3):e70079. doi: 10.1002/alz.70079. Alzheimers Dement. 2025. PMID: 40145329 Free PMC article. Review.
References
-
- Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli M, Hampel H, Scheltens P, Tierney MC, Whitehouse P, Winblad B (2006) Mild cognitive impairment. Lancet 367, 1262–1270. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical